ArticleOncoimmunology2015
Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Trial
- Cell-type-specific requirement for TYK2 in murine immune cells under steady state and challenged conditions.Cellular and molecular life sciences : CMLS · 2025Article
- Lack of TYK2 signaling enhances host resistance to Candida albicans skin infection.Nature communications · 2024Article
- Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors.Current medicinal chemistry · 2024Review
- Tyk2 is a tumor suppressor in colorectal cancer.Oncoimmunology · 2022Article
- Review
- Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?Cancers · 2021Review
- Tyrosine Kinase 2 Signalling Drives Pathogenic T cells in Colitis.Journal of Crohn's & colitis · 2021Article
- TYK2 licenses non-canonical inflammasome activation during endotoxemia.Cell death and differentiation · 2021Article
- From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases.Frontiers in genetics · 2021Review
- Knockdown of GSG2 inhibits prostate cancer progression in vitro and in vivo.International journal of oncology · 2020Article
- TYK2 in Tumor Immunosurveillance.Cancers · 2020Review
- STAT1 Isoforms Differentially Regulate NK Cell Maturation and Anti-tumor Activity.Frontiers in immunology · 2020Article
- NK Cells Require Cell-Extrinsic and -Intrinsic TYK2 for Full Functionality in Tumor Surveillance and Antibacterial Immunity.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation.Frontiers in immunology · 2019Review
- Compound heterozygous TYK2 mutations underlie primary immunodeficiency with T-cell lymphopenia.Scientific reports · 2018Article
- Canonical and Non-Canonical Aspects of JAK-STAT Signaling: Lessons from Interferons for Cytokine Responses.Frontiers in immunology · 2017Review
- STATs in NK-Cells: The Good, the Bad, and the Ugly.Frontiers in immunology · 2016Review
- Immunological Consequences of JAK Inhibition: Friend or Foe?Current hematologic malignancy reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
Tyrosine kinase 2 (TYK2) is a Janus kinase (JAK) that is crucially involved in inflammation, carcinogenesis and defense against infection. The cytotoxic activity of natural killer (NK) cells in TYK2-deficient (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.